Whalesbook
Kyun Nahi Mila Extended Patent?
Asal mein, AbbVie ne khud hi opposition proceedings se withdraw kar liya tha, aur ab May 7, 2026 ko Patent Office ne application ko official taur par reject kar diya. Yeh specific bilayer tablet formulation ke liye tha, jo drug ke original patent se alag tha. Abb yeh drug India mein apni original patent expiry ke baad zyada time tak monopoly enjoy nahi kar payega.
Global Market Aur India Ka Scene
Waisey toh Hepatitis C treatment ka global market $10 billion se bhi upar jaane wala hai 2033 tak. North America aur Europe bade markets hain, par Asia Pacific, jisme India bhi hai, sabse fast grow kar raha hai. India mein estimated 35 million log Hepatitis C se affected hain, toh yahan market kaafi bada hai.
Maviret ek top drug hai, par competition bhi tagda hai Gilead, Merck, aur Johnson & Johnson jaise companies se. India ka patent law kaafi strict hai, khas kar ke jab baat patent extensions ki ho. Section 3(d) ke wajah se, sirf minor changes wale drugs ko tab tak patent nahi milta jab tak unki therapeutic effectiveness mein koi bada improvement na ho. AbbVie ko pehle bhi Venetoclax aur Rinvoq jaise drugs ke liye patent issues face karne pade hain India mein.
Generic Drugs Ki Entry Aur AbbVie Par Pressure
Iss patent rejection se India mein Maviret ke affordable generic versions jaldi aa sakte hain. Jab saste options available honge, toh AbbVie ke drug ki pricing power aur market share par pressure aayega. Company ke liye yeh revenue projections ko bhi affect kar sakta hai, especially in emerging markets jahan affordability matter karti hai.
Investors Kya Soch Rahe Hain?
AbbVie ka P/E ratio around 103 hai, matlab investors ko future growth ki kaafi umeed hai. Par India mein baar-baar patent issues aane se unki concern badh sakti hai ki company kaise apni drugs ko extended periods tak protect kar paayegi, especially in key markets.
Analyst log abhi bhi AbbVie par generally positive hain, aur 'Buy' rating de rahe hain, price targets $235 ke upar set kar rahe hain. Woh company ke immunology, oncology sectors aur future pipeline par bharosa kar rahe hain. Lekin, regulatory hurdles aur Indian market ke complexities ko bhi consider karna hoga. AbbVie ko apni strategy adjust karni padegi taaki woh Hepatitis C franchise se revenue maintain kar sake, especially jab generic competition badh rahi hai.